远程缺血适应对急性中度缺血性卒中患者神经功能的影响:RICAMIS随机临床试验
RICAMIS多中心、开放标签、盲法终点随机临床试验纳入中国55家医院1893例急性中度缺血性卒中患者,症状发作48小时内随机分为RIC组(n=922,双上肢加压至200 mm Hg,5分钟充气/5分钟放气,5个循环,10-14天,作为指南治疗辅助)或单纯指南治疗组(n=971)。主要终点90天改良Rankin量表0-1分的比例RIC组67.4% vs 对照组62.0%(风险差5.4%[95%CI 1.0%-9.9%];OR 1.27[95%CI 1.05-1.54];P=.02)。任何不良事件发生率RIC组6.8%(59/863)vs 对照组5.6%(51/913)。作者结论认为RIC显著提高90天良好神经功能可能性,但需另一项试验重复验证后方可确定疗效。
要点
- 急性中度缺血性卒中症状发作48小时内启动RIC(双上肢200 mm Hg,5分钟充气/5分钟放气,5个循环,10-14天)作为指南治疗辅助,90天mRS 0-1分比例67.4% vs 62.0%(风险差5.4%[95%CI 1.0%-9.9%];OR 1.27[95%CI 1.05-1.54];P=.02)。
- 任何不良事件发生率RIC组6.8%(59/863)vs 对照组5.6%(51/913)。
- 该试验为多中心、开放标签、盲法终点设计,纳入1893例,1776例(93.8%)完成试验。
- 作者结论:RIC较常规治疗显著提高90天良好神经功能可能性,但需另一项试验重复验证后方可确定疗效。
适用人群与场景
- 急性中度缺血性卒中成人患者,症状发作48小时内随机入组;纳入中国55家医院,年龄均值(SD)65(10.3)岁,女性606例(34.1%)。
诊断标准与关键阈值
- 主要终点良好功能结局定义为90天改良Rankin量表评分0-1分。
处置流程与药物剂量
- RIC组:使用气动电子装置对双上肢加压至200 mm Hg,5分钟充气/5分钟放气为1个循环,共5个循环,持续10-14天,作为指南基础治疗的辅助(n=922)。
- 对照组:仅指南基础治疗(n=971)。
研究设计与关键结果
- 多中心、开放标签、盲法终点随机临床试验,2018年12月26日至2021年1月19日在中国55家医院纳入1893例急性中度缺血性卒中患者,最终随访日期2021年4月19日;随机分组RIC组n=922、对照组n=971;1776例(93.8%)完成试验。
- 主要终点:90天mRS 0-1分比例RIC组582例(67.4%)vs 对照组566例(62.0%),风险差5.4%(95%CI 1.0%-9.9%),OR 1.27(95%CI 1.05-1.54),P=.02。
- 任何不良事件:RIC组6.8%(59/863)vs 对照组5.6%(51/913)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、盲法终点随机临床试验(RICAMIS,ClinicalTrials.gov NCT03740971)。
- 局限:作者结论指出这些发现需在另一项试验中重复验证后方可确定该干预的疗效。
对床旁实践的改变
- 作者认为,在急性中度缺血性卒中成人中,与常规治疗相比,远程缺血适应治疗显著提高了90天良好神经功能的可能性;但作者同时指出,在确定该干预疗效前需另一项试验重复验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Preclinical and clinical studies have suggested a neuroprotective effect of remote ischemic conditioning (RIC), which involves repeated occlusion/release cycles on bilateral upper limb arteries; however, robust evidence in patients with ischemic stroke is lacking.
OBJECTIVE: To assess the efficacy of RIC for acute moderate ischemic stroke.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded-end point, randomized clinical trial including 1893 patients with acute moderate ischemic stroke was conducted at 55 hospitals in China from December 26, 2018, through January 19, 2021, and the date of final follow-up was April 19, 2021.
INTERVENTIONS: Eligible patients were randomly assigned within 48 hours after symptom onset to receive treatment with RIC (using a pneumatic electronic device and consisting of 5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mm Hg) for 10 to 14 days as an adjunct to guideline-based treatment (n = 922) or guideline-based treatment alone (n = 971).
MAIN OUTCOMES AND MEASURES: The primary end point was excellent functional outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1. All end points had blinded assessment and were analyzed on a full analysis set.
RESULTS: Among 1893 eligible patients with acute moderate ischemic stroke who were randomized (mean [SD] age, 65 [10.3] years; 606 women [34.1%]), 1776 (93.8%) completed the trial. The number with excellent functional outcome at 90 days was 582 (67.4%) in the RIC group and 566 (62.0%) in the control group (risk difference, 5.4% [95% CI, 1.0%-9.9%]; odds ratio, 1.27 [95% CI, 1.05-1.54]; P = .02). The proportion of patients with any adverse events was 6.8% (59/863) in the RIC group and 5.6% (51/913) in the control group.
CONCLUSIONS AND RELEVANCE: Among adults with acute moderate ischemic stroke, treatment with remote ischemic conditioning compared with usual care significantly increased the likelihood of excellent neurologic function at 90 days. However, these findings require replication in another trial before concluding efficacy for this intervention.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03740971.
参考来源
- Chen HS, Cui Y, Li XQ, et al. Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial. JAMA. 2022. PMID: 35972485. doi:10.1001/jama.2022.13123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。